Welcome to our dedicated page for Waters news (Ticker: WAT), a resource for investors and traders seeking the latest updates and insights on Waters stock.
Waters Corporation (NYSE: WAT) is a global company in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. This news page aggregates announcements, press releases, and corporate updates related to Waters, giving readers a focused view of developments that affect the company and its markets.
Investors and industry professionals can use this feed to follow Waters’ product launches, financial results, and strategic initiatives. Recent news has highlighted new technologies such as the Xevo Charge Detection Mass Spectrometer (CDMS), which Waters describes as enabling direct mass detection for large biomolecules relevant to next-generation therapeutics, and a Charged Aerosol Detector designed for use with the company’s Empower chromatography data system. These announcements illustrate how Waters is addressing analytical challenges in pharmaceuticals, biotherapeutics, food analysis, and environmental testing.
The news stream also features quarterly earnings releases, where Waters reports sales performance, instrument and recurring revenue trends, and commentary from management. In addition, Waters issues updates on investor conference presentations and on the planned combination with BD’s Biosciences & Diagnostic Solutions business via a Reverse Morris Trust transaction, as described in its press releases and Form 8-K filings.
By reviewing Waters-related news in one place, readers can track themes such as instrument replacement cycles, adoption of new chromatography and mass spectrometry products, and the company’s expansion into adjacencies like bioseparations, bioanalytical characterization, and multiplex diagnostics. Bookmark this page to monitor ongoing disclosures and media releases that shape the narrative around WAT stock and Waters’ role in regulated, high-volume testing and scientific markets.
Waters Corporation (NYSE:WAT) will report Q1 2026 results and host a conference call on May 5, 2026 at 8:30 a.m. ET.
A live webcast will be available on Waters Investor Relations, and a replay will remain available through at least June 2, 2026.
Waters (NYSE: WAT) launched the omniDAWN Multi-Angle Light Scattering (MALS) Photometer, the first extended-range MALS detector for UHPLC/UPLC workflows, available globally in summer 2026. The 18-angle detector enables up to 4x faster run times, 10x extended sizing (~50–500 nm radius), and reduces sample use by 30–50% and solvent use by ~40%.
Powered by ASTRA Software and integrating UV and RI detection, omniDAWN delivers absolute molar mass and size measurements for aggregates, viral vectors, LNPs, ADCs, and advanced materials; Empower compatibility is planned later this year.
Waters (NYSE: WAT) announced U.S. FDA clearance (April 8, 2026) of the Onclarity HPV Self-Collection Kit and FDA approval of the BD Onclarity HPV Assay for at-home use. The assay provides extended genotyping (six individual types, three pooled groups) and works with the automated BD COR System.
The kit aims to increase screening access for unscreened or under-screened individuals (about 60% of cervical cancer cases) and will be available by prescription in coming months, covered by private insurance, Medicaid, and Medicare.
Waters (NYSE: WAT) priced a $3.5 billion offering of senior notes issued by subsidiary Augusta SpinCo, split across five tranches maturing 2027, 2029, 2031, 2033 and 2036 with coupon rates from 4.321% to 5.245% at 100% issue price.
Proceeds, together with cash on hand, are intended to repay the $3.5 billion delayed draw term loan; closing expected on or about March 23, 2026, subject to customary conditions.
Waters (NYSE: WAT) launched the ARES-G3 Rheometer on March 9, 2026, a next-generation TA Instruments product that boosts data capture and speeds up testing.
The instrument captures up to 25,000 data points per second, delivers up to 10x the data rate of its predecessor, and can cut standard test times by up to 80%, enabling faster workflows and reduced calibrations.
Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., President and CEO, will speak in a fireside chat at the TD Cowen Health Care Conference on March 2, 2026 at 11:10 AM ET.
A live webcast will stream on the company's Events & Presentations investor site and a replay will be available for 90 days.
Waters (NYSE: WAT) launched 1 mm I.D. microflow LC columns with MaxPeak Premier Technology on February 17, 2026, for ACQUITY, BioResolve, and GTxResolve brands. The columns claim up to 2× higher sensitivity, use up to 75% less sample, and reduce solvent use by up to 4× versus 2.1 mm I.D. columns, improving recovery for small molecules, peptides, and oligonucleotides while enabling earlier reproducible results and global availability with immediate shipment.
BD (NYSE: BDX) completed the spin-off and combination of its Biosciences & Diagnostic Solutions business with Waters Corporation (NYSE: WAT) on Feb 9, 2026. BD received $4.0 billion in cash and shareholders received ~0.135 WAT shares per BDX share, with cash for fractions.
As of closing BD shareholders held 39.2% of the combined company (fully diluted). Based on WAT's Feb 6, 2026 close, the business was valued at $18.8 billion. BD expects to use $2.0 billion for an accelerated share repurchase and $2.0 billion to repay debt. Claire M. Fraser joined the Waters board and stepped down from the BD board.
Waters (NYSE: WAT) has completed its combination with Becton, Dickinson and Company's Biosciences & Diagnostic Solutions businesses, creating a global life sciences and diagnostics leader organized into four divisions: Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics, and Waters Materials Sciences. The transaction used a Reverse Morris Trust, and post-close ownership is Waters 60.8% and BD shareholders 39.2% on a fully diluted basis. Claire M. Fraser, Ph.D., joined the Waters Board, expanding it to 11 members. Barclays advised Waters; Kirkland & Ellis served as lead counsel.
Waters Corporation (NYSE: WAT) reported Q4 2025 sales of $932 million, up 7% as reported (6% constant currency), with GAAP EPS $3.77 and non-GAAP EPS $4.53 (+10%). Full-year 2025 sales were $3,165 million (+7%) and non-GAAP EPS was $13.13 (+11%).
The company closed its acquisition of BD Biosciences and Diagnostic Solutions, expecting an owned-period contribution of approximately $3.0 billion and total 2026 reported revenue of $6.405–6.455 billion. 2026 non-GAAP EPS guidance is $14.30–14.50.